Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

331
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Androgen Deprivation Therapy and Cardiovascular Health: Challenges and Opportunities in Prostate Cancer Care.

Archivos espanoles de urologia·2026
Same author

Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis.

Breast cancer research and treatment·2026
Same author

Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active Surveillance.

Cancers·2026
Same author

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial.

BMJ open·2026
Same author

The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.

Current oncology (Toronto, Ont.)·2026
Same author

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

European urology oncology·2026

Related Experiment Video

Updated: Jun 12, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.6K

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials.

Thomas A C Kennedy1, Wee Loon Ong2, Harvey Quon3

  • 1Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

International Journal of Radiation Oncology, Biology, Physics
|September 18, 2024
PubMed
Summary

Stereotactic ablative radiotherapy (SABR) provides excellent long-term control for localized prostate cancer. While second malignancies can occur, the risk is comparable to general population rates, ensuring good overall survival.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Related Experiment Videos

Last Updated: Jun 12, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Stereotactic ablative radiotherapy (SABR) is increasingly adopted for localized prostate cancer treatment.
  • Randomized trials indicate SABR's noninferiority to conventional or hypofractionated radiation therapy.
  • Long-term outcome data for SABR in prostate cancer remain limited.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of SABR for low- and intermediate-risk localized prostate cancer.
  • To assess disease control, survival rates, and the occurrence of second malignancies after SABR.
  • To provide prospective data on extended surveillance outcomes.

Main Methods:

  • A prospective analysis of 267 patients with low- and intermediate-risk prostate cancer from 3 Canadian clinical trials (2006-2013).
  • Patients received SABR (35-40 Gy in 5 fractions).
  • Outcomes including PSA, metastasis, vital status, and second malignancies (classified by modified Cahan's criteria) were prospectively recorded.

Main Results:

  • Median follow-up was 10.3 years.
  • Ten-year biochemical failure was 7.7%.
  • Ten-year overall survival was 84.1%, prostate cancer-specific survival was 99.2%, and freedom from metastasis was 98.8%.
  • Second malignancy occurred in 10.1% of patients, with 22.2% possibly or likely related to radiation.
  • Ten-year freedom from second malignancy was 89.2%.

Conclusions:

  • SABR demonstrates excellent long-term disease control for localized prostate cancer.
  • The risk of second malignancy following SABR is moderate and consistent with population background rates.
  • SABR is a safe and effective treatment option with durable outcomes.